A new draft guidance focuses on obtaining tentative approval — granted for drugs that cannot be marketed in the U.S. because of existing patents or exclusivity — for various HIV treatment and prevention drugs intended for distribution outside the U.S. under the President’s Emergency Plan for AIDS Relief (PEPFAR).
Source: Drug Industry Daily